The legislation, which explicitly names WuXi, must pass the U.S. Senate before it can be sent to the president to be signed into law, Reuters reported.
"They (WuXi) are looking to reduce their scope and perhaps preparing for reduction in contracts," BTIG analyst Justin Zelin said.
The Financial Times had reported in October that WuXi and WuXi AppTec are planning to sell some of their operations.
"Especially with the newly entering administration being increasingly hawkish against China specifically ... there is broad support for the act conceptually. But it will need to find a larger legislative vehicle to become law," Zelin added.
The bill is designed to keep Americans' personal health and genetic information from foreign adversaries and encourage U.S. pharmaceutical and biotech companies to reduce their reliance on China for drug ingredient manufacturing and early research.
WuXi AppTec had said in December its units had signed a deal with U.S.-based private equity firm Altaris LLC for the sale of the U.S. and UK-based operations of its cell and gene therapy unit.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.